A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents (Q38544824)

4 September 2017

1 reference

title

A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents (English)

1 reference

4 September 2017

0 references

0 references

0 references

0 references

2

1 reference

4 September 2017

Mahesh A Barmade

3

0 references

author name string

Mayank Kumar Sharma

series ordinal

1

1 reference

PubMed ID

26161824

4 September 2017

Rajani Giridhar

series ordinal

4

1 reference

PubMed ID

26161824

4 September 2017

Mange Ram Yadav

series ordinal

5

1 reference

PubMed ID

26161824

4 September 2017

language of work or name

English

0 references

publication date

10 July 2015

1 reference

Expert Opinion on Therapeutic Patents

4 September 2017

1 reference

4 September 2017

25

1 reference

4 September 2017

10

1 reference

4 September 2017

1093-1116

1 reference

Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013

4 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Obesity, a health burden of a global nature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Anti-obesity drugs: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

New drug targets for the treatment of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Endocannabinoids: synthesis and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Minireview: Endocannabinoids and their receptors as targets for obesity therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Evidence for novel cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Molecular characterization of a peripheral receptor for cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

CB(1) cannabinoid receptor-G protein association: a possible mechanism for differential signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

The endocannabinoid signalling system: biochemical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Signal transduction of the CB1 cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Current knowledge on the antagonists and inverse agonists of cannabinoid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Allosteric modulation of the cannabinoid CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Endocannabinoid control of food intake and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Activation of the peripheral endocannabinoid system in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

The role of the endocannabinoid system in lipogenesis and fatty acid metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1064898

10.1517/13543776.2015.1064898

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3lw3swahcrf2tcxq3bddkwcdnu

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_3lw3swahcrf2tcxq3bddkwcdnu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3lw3swahcrf2tcxq3bddkwcdnu

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/3lw3swahcrf2tcxq3bddkwcdnu